Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin. Methods: We carried out a retrospective study of the use of dalbavancin in 55 patients at the Azienda Ospedaliera Ospedali Riuniti Umberto I (Ancona, Italy) from February 2017 to May 2020 and compared “on label” and “off label” use of dalbavancin in ABSSSI and non-ABSSSI. Results: A total of 55 patients were included in the study. The median age was 61 years; 51% had ABSSSI; 24% had prosthetic joint infections, and 14% had osteomyelitis. A total of 53% received a single 1500 mg infusion of dalbavancin, and 18% received a second dose 14 days later; 24% of patients received further doses at 14-day intervals. In 91% of cases, patients achieved clinical objectives with dalbavancin: 96% of patients with ABSSSI and 69% of those with prosthetic joint infections. Conclusions: Dalbavancin was shown to have an excellent tolerability profile and to be a highly successful therapeutic approach even in those cases treated “off-label”.

中文翻译：

---

达巴万星在皮肤、骨骼和关节感染中的应用：意大利中心的真实体验

达巴万星是一种脂糖肽，被批准用于治疗急性细菌性皮肤和皮肤结构感染 (ABSSSI)。该研究的目的是评估所有接受至少一次达巴万星给药的患者的疗效和安全性。方法：我们对 2017 年 2 月至 2020 年 5 月在 Azienda Ospedaliera Ospedali Riuniti Umberto I（意大利安科纳）的 55 名患者中使用达巴万星进行了一项回顾性研究，并比较了达巴万星在ABSSSI 和非 ABSSSI。结果：本研究共纳入 55 名患者。中位年龄为 61 岁；51% 有 ABSSSI；24% 有假体关节感染，14% 有骨髓炎。总共 53% 的人接受了单次 1500 毫克的达巴万星输注，18% 的人在 14 天后接受了第二剂；24% 的患者每隔 14 天接受一次进一步的剂量。在 91% 的病例中，达巴万星的患者达到了临床目标：96% 的 ABSSSI 患者和 69% 的假体关节感染患者。结论：达巴万星被证明具有出色的耐受性，即使在那些“标签外”治疗的情况下也是一种非常成功的治疗方法。